Annals of Oncology Advance Access published online on February 17, 2005
Annals of Oncology, doi:10.1093/annonc/mdi098
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 International Agency for Research on Cancer, Lyon, France
* To whom correspondence should be addressed. Background: There are no recent estimates of the incidence and mortality from cancer at a European level. Those data that are available generally refer to the mid-1990s and are of limited use for cancer control planning. We present estimates of the cancer burden in Europe in 2004, including data for the (25 Member States) European Union. Methods: The most recent sources of incidence and mortality data available in the Descriptive Epidemiology Group at IARC were applied to population projections to derive the best estimates of the burden of cancer, in terms of incidence and mortality, for Europe in 2004. Results: In 2004 in Europe, there were an estimated 2 886 800 incident cases of cancer diagnosed and 1 711 000 cancer deaths. The most common incident form of cancer was lung cancer (13.3% of all incident cases), followed by colorectal cancer (13.2%) and breast cancer (13%). Lung cancer was also the most common cause of cancer death (341 800 deaths), followed by colorectal (203 700), stomach (137 900) and breast (129 900). Conclusions: With an estimated 2.9 million new cases (54% occurring in men, 46% in women) and 1.7 million deaths (56% in men, 44% in women) each year, cancer remains an important public health problem in Europe, and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant. To make great progress quickly against cancer in Europe, the need is evident to make a concerted attack on the big killers: lung, colorectal, breast and stomach cancer. Stomach cancer rates are falling everywhere in Europe and public health measures are available to reduce the incidence and mortality of lung cancer, colorectal cancer and breast cancer.
Received December 7, 2004
Accepted December 9, 2004
Original article
Cancer incidence and mortality in Europe, 2004
P. Boyle, E-mail: director{at}iarc.fr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann. Onc., June 1, 2008; 19(6): 1160 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Khan, V. Gallo, J. Linseisen, R. Kaaks, S. Rohrmann, O. Raaschou-Nielsen, A. Tjonneland, H. E. Johnsen, K. Overvad, M. M. Bergmann, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition Haematologica, June 1, 2008; 93(6): 842 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nieters, S. Rohrmann, N. Becker, J. Linseisen, T. Ruediger, K. Overvad, A. Tjonneland, A. Olsen, N. E. Allen, R. C. Travis, et al. Smoking and Lymphoma Risk in the European Prospective Investigation into Cancer and Nutrition Am. J. Epidemiol., May 1, 2008; 167(9): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Persson, U Ostlund, A Wennman-Larsen, Y Wengstrom, and P Gustavsson Health-related quality of life in significant others of patients dying from lung cancer Palliative Medicine, April 1, 2008; 22(3): 239 - 247. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A.C. Ruiter, J. de Nooijer, G. van Breukelen, C. F. Ockhuysen-Vermey, and H. de Vries Intended Coping Responses to Cancer Symptoms in Healthy Adults: The Roles of Symptom Knowledge, Detection Behavior, and Perceived Threat Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 818 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Martinez-Torrecuadrada, L. H. Cheung, P. Lopez-Serra, R. Barderas, M. Canamero, S. Ferreiro, M. G. Rosenblum, and J. I. Casal Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis Mol. Cancer Ther., April 1, 2008; 7(4): 862 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bosetti, P. Bertuccio, F. Levi, F. Lucchini, E. Negri, and C. La Vecchia Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis Ann. Onc., April 1, 2008; 19(4): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boyle Favorable trends in cancer mortality in the European Union but no room for complacency Ann. Onc., April 1, 2008; 19(4): 605 - 606. [Full Text] [PDF]
|
|
|
|
|
|
D. Connolly, A. Black, A. Gavin, P. F. Keane, and L. J. Murray Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Dabakuyo, F. Bonnetain, P. Roignot, M.-L. Poillot, G. Chaplain, T. Altwegg, G. Hedelin, and P. Arveux Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival Ann. Onc., February 1, 2008; 19(2): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann. Onc., December 6, 2007; (2007) mdm488v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dimopoulos, A. Spencer, M. Attal, H. M. Prince, J.-L. Harousseau, A. Dmoszynska, J. S. Miguel, A. Hellmann, T. Facon, R. Foa, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma N. Engl. J. Med., November 22, 2007; 357(21): 2123 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Troiani, N. J. Serkova, D. L. Gustafson, T. K. Henthorn, O. Lockerbie, A. Merz, M. Long, M. Morrow, F. Ciardiello, and S. G. Eckhardt Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model Clin. Cancer Res., November 1, 2007; 13(21): 6450 - 6458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B Ballinger and C. Anggiansah Colorectal cancer BMJ, October 6, 2007; 335(7622): 715 - 718. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tot The Theory of the Sick Breast Lobe and the Possible Consequences International Journal of Surgical Pathology, October 1, 2007; 15(4): 369 - 375. [Abstract] [PDF]
|
|
|
|
|
|
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Di Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omede, M. T. Ambrosini, et al. Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network J. Clin. Oncol., October 1, 2007; 25(28): 4459 - 4465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arbyn, A. O. Raifu, P. Autier, and J. Ferlay Burden of cervical cancer in Europe: estimates for 2004 Ann. Onc., October 1, 2007; 18(10): 1708 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Belluco, E. F. Petricoin, E. Mammano, F. Facchiano, S. Ross-Rucker, D. Nitti, C. Di Maggio, C. Liu, M. Lise, L. A. Liotta, et al. Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer Ann. Surg. Oncol., September 1, 2007; 14(9): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Klaeser, O Wiederkehr, D Koeberle, A Mueller, B Bubeck, and B Thuerlimann Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer Ann. Onc., August 1, 2007; 18(8): 1329 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Arbyn, P Autier, and J Ferlay Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004 Ann. Onc., August 1, 2007; 18(8): 1423 - 1425. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Manochakian, K. C. Miller, and A. A. Chanan-Khan Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Oncologist, August 1, 2007; 12(8): 978 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al. Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Borget, C Corone, M Nocaudie, M Allyn, S Iacobelli, M Schlumberger, and G De Pouvourville Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal Eur. J. Endocrinol., May 1, 2007; 156(5): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Demirkan, A. Alacacioglu, and U. Yilmaz Relation of Body Mass Index (BMI) to Disease Free (DFS) and Distant Disease Free Survivals (DDFS) Among Turkish Women with Operable Breast Carcinoma Jpn. J. Clin. Oncol., April 1, 2007; 37(4): 256 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barrabes, L. Pages-Pons, C. M. Radcliffe, G. Tabares, E. Fort, L. Royle, D. J. Harvey, M. Moenner, R. A. Dwek, P. M. Rudd, et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer Glycobiology, April 1, 2007; 17(4): 388 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Boncz, A Sebestyen, L Dobrossy, Z Pentek, A Budai, A Kovacs, C Dozsa, and I Ember The organisation and results of first screening round of the Hungarian nationwide organised breast cancer screening programme Ann. Onc., April 1, 2007; 18(4): 795 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Ferlay, P Autier, M Boniol, M Heanue, M Colombet, and P Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann. Onc., March 1, 2007; 18(3): 581 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al. Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Cleries, J Ribes, L Esteban, J. Martinez, and J. Borras Time trends of breast cancer mortality in Spain during the period 1977-2001 and Bayesian approach for projections during 2002-2016 Ann. Onc., December 1, 2006; 17(12): 1783 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Cai, Y.-T. Gao, W.-H. Chow, X.-O. Shu, G. Yang, B.-T. Ji, W. Wen, N. Rothman, H.-L. Li, J. D. Morrow, et al. Prospective Study of Urinary Prostaglandin E2 Metabolite and Colorectal Cancer Risk J. Clin. Oncol., November 1, 2006; 24(31): 5010 - 5016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al. Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 1, 2006; 24(31): 5025 - 5033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gabriel, A. zur Hausen, E. Stickeler, C. Dietz, G. Gitsch, D.-C. Fischer, J. Bouda, C. Tempfer, and A. Hasenburg Weak Expression of Focal Adhesion Kinase (pp125FAK) in Patients with Cervical Cancer Is Associated with Poor Disease Outcome Clin. Cancer Res., April 15, 2006; 12(8): 2476 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Savage, L. Hou, J. Lissowska, W.-H. Chow, W. Zatonski, S. J. Chanock, and M. Yeager Interleukin-8 polymorphisms are not associated with gastric cancer risk in a polish population. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 589 - 591. [Full Text] [PDF]
|
|
|
|
|
|
A. Tavani, L. Giordano, S. Gallus, R. Talamini, S. Franceschi, A. Giacosa, M. Montella, and C. La Vecchia Consumption of sweet foods and breast cancer risk in Italy Ann. Onc., February 1, 2006; 17(2): 341 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Van Cutsem and F. Costa Progress in the Adjuvant Treatment of Colon Cancer: Has It Influenced Clinical Practice? JAMA, December 7, 2005; 294(21): 2758 - 2760. [Full Text] [PDF]
|
|
|
|
|
|
T. Fisch, P. Pury, N. Probst, A. Bordoni, C. Bouchardy, H. Frick, G. Jundt, D. De Weck, E. Perret, and J.-M. Lutz Variation in survival after diagnosis of breast cancer in Switzerland Ann. Onc., December 1, 2005; 16(12): 1882 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-M. Kim, S.-H. Yim, J.-S. Lee, M.-S. Kwon, J.-W. Ryu, H.-M. Kang, H. Fiegler, N. P. Carter, and Y.-J. Chung Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non-Small Cell Lung Cancers Clin. Cancer Res., December 1, 2005; 11(23): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Andre and W Schmiegel CHEMORADIOTHERAPY FOR COLORECTAL CANCER Gut, August 1, 2005; 54(8): 1194 - 1202. [Full Text] [PDF]
|
|
|
|
|
|
E. Kralikova, E. Podmaniczky, H. Stypulkowska-Misiurewicz, E. Kavcova, A. Veryga, and T. Muller Making the transition to action BMJ, July 23, 2005; 331(7510): 191 - 192. [Full Text] [PDF]
|
|